Covid-19 Vaccination in Patients with Inflammatory Bowel Diseases
- Conditions
- Inflammatory Bowel Diseases
- Registration Number
- DRKS00025694
- Lead Sponsor
- Medizinische Hochschule Hannover
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 23
Inclusion Criteria
Male and female patients aged =18 years
- History of inflammatory bowel disease (>3 months)
- IBD patients prior to Covid-19 vaccination
- Written informed consent from the patient
Exclusion Criteria
- Conditions that do not allow the subject to appreciate the nature, scope, and possible consequences of the clinical trial.
- Indications that the patient is unlikely to comply with the protocol (e.g., unwillingness to cooperate)
- Covid-19 vaccination already administered.
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Characterization of the cellular and humoral immune response after Covid-19 vaccination in IBD (Inflammatory Bowel Diseases) patients.
- Secondary Outcome Measures
Name Time Method Differentiation of the immune response after Covid-19 vaccination under different immunosuppressive therapies in IBD patients. Evaluation of the influence if Covid-19 vaccination on IBD disease progression. Evaluation of negative predictive factors on vaccination response after Covid-19 vaccination in IBD patients.